Open Label Phase II Clinical Trial of Orteronel (TAK-700) in Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors. The Greko II Study.
Phase of Trial: Phase II
Latest Information Update: 06 Mar 2018
Price : $35 *
At a glance
- Drugs Orteronel (Primary)
- Indications Ovarian cancer
- Focus Therapeutic Use
- Acronyms Greko II
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 11 Feb 2017 Status changed from recruiting to discontinued.
- 07 Jun 2016 Trial design presented at the 52nd Annual Meeting of the American Society of Clinical Oncology